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Sir
In a recent study published in the British Journal of Cancer,
Salgado and colleagues demonstrated a correlation between serum
IL-6 levels, serum VEGF levels and platelet count in patients with
advanced cancer. Patients with a thrombocytosis had median
VEGF serum concentrations ´ 3.2, and median IL-6 serum levels
´ 5.8, higher than other patients. Growth factors and cytokines
such as IL-6 may affect both platelet number and function,
including the capacity of platelets to store angiogenic factors such
as VEGF. This is supported by the observation that IL-6 levels
were also found to correlate with the VEGF load per platelet
(VEGFPLT) (Salgado et al, 1999).
We have recently demonstrated a close correlation between
platelet counts and serum VEGF levels in patients with renal cell
cancer (RCC). Platelet counts and VEGF levels ³ the median for
the group indicated a poor outcome (O’Byrne et al, 1999). In reply
to our report Gunsillius and colleagues recommended we calculate
the VEGFPLT in the patients in our study and assess its impact on
outcome (Gunsilius et al, 1999). The mean VEGFPLT value for the
whole group was 1.29 pg/106 platelets (range 0.13–4.06). This is
similar to that found by Salgado and colleagues where the mean
value was 1.37 pg/106 (range 0.16–3.64). Patients with VEGFPLT
levels ³ median had a significantly worse outcome than those with
lower levels (P = 0.025, Figure 1). Whilst there was a trend for
VEGFPLT concentrations to be higher in patients with platelet
counts ³ median value for the group this was not significant 
(P = 0.174).
The prognostic significance of VEGFPLT may be due to high local
release of VEGF by platelets activated in solid tumours potentially
leading to enhanced angiogenesis. The activation of platelets may
occur through their adherence to tumour-related endothelium or by
their extravasation through hyperpermeable microvessels with
subsequent exposure to subendothelial matrix proteins (Pinedo 
et al, 1998; O’Byrne et al, 1999). The relatively wide range of
VEGFPLT levels seen in these studies is likely to reflect, at least in
part, the activity of cytokines such as IL-6 overexpressed in RCC.
The correlation with VEGFPLT provides an explanation for the
observation that elevated serum IL-6 levels are associated with a
poor outcome in solid tumours including RCC (Dosquet et al,
1997). These results also lend support to the contention of Pinedo
and colleagues of an important role for platelets in the process of
tumour-related angiogenesis (Pinedo et al, 1998).
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vegf/plt < 1.29 pg (median survival: 334 days, n = 16)
vegf/plt   1.29 pg (median survival: 200 days, n = 17)
Figure 1 Survival difference between patients with vegf/platelet ratio above and below the group median (1.29 pg) prior to treatment